Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Modelling the MYC-driven normal-to-tumour switch in breast cancer.

Lourenco C, Kalkat M, Houlahan KE, De Melo J, Longo J, Done SJ, Boutros PC, Penn LZ.

Dis Model Mech. 2019 Jul 26;12(7). pii: dmm038083. doi: 10.1242/dmm.038083.

2.

An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.

Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, Wang Y, Chen EX, Hamilton RJ, Sweet JM, van der Kwast TH, Fleshner NE, Penn LZ.

Mol Metab. 2019 Jul;25:119-130. doi: 10.1016/j.molmet.2019.04.003. Epub 2019 Apr 10.

3.

MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis.

Kalkat M, Resetca D, Lourenco C, Chan PK, Wei Y, Shiah YJ, Vitkin N, Tong Y, Sunnerhagen M, Done SJ, Boutros PC, Raught B, Penn LZ.

Mol Cell. 2018 Dec 6;72(5):836-848.e7. doi: 10.1016/j.molcel.2018.09.031. Epub 2018 Nov 8.

PMID:
30415952
4.

MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.

Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-Awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ.

Cancer Cell. 2018 Oct 8;34(4):579-595.e8. doi: 10.1016/j.ccell.2018.09.001.

5.

MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability.

Dingar D, Tu WB, Resetca D, Lourenco C, Tamachi A, De Melo J, Houlahan KE, Kalkat M, Chan PK, Boutros PC, Raught B, Penn LZ.

Nat Commun. 2018 Aug 29;9(1):3502. doi: 10.1038/s41467-018-05660-0.

6.

Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins.

Yu R, Longo J, van Leeuwen JE, Mullen PJ, Ba-Alawi W, Haibe-Kains B, Penn LZ.

Cancer Res. 2018 Mar 1;78(5):1347-1357. doi: 10.1158/0008-5472.CAN-17-1231. Epub 2017 Dec 11.

7.

Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism.

De Melo J, Kim SS, Lourenco C, Penn LZ.

Oncogene. 2017 Dec 7;36(49):6815-6822. doi: 10.1038/onc.2017.268. Epub 2017 Aug 14.

PMID:
28806398
8.

Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth.

Lustig LC, Dingar D, Tu WB, Lourenco C, Kalkat M, Inamoto I, Ponzielli R, Chan WCW, Shin JA, Penn LZ.

Oncogene. 2017 Dec 7;36(49):6830-6837. doi: 10.1038/onc.2017.275. Epub 2017 Aug 14.

PMID:
28806396
9.

MYC Deregulation in Primary Human Cancers.

Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ.

Genes (Basel). 2017 May 25;8(6). pii: E151. doi: 10.3390/genes8060151. Review.

10.

Guiding principles for a successful multidisciplinary research collaboration.

Lustig LC, Ponzielli R, Tang PS, Sathiamoorthy S, Inamoto I, Shin JA, Penn LZ, Chan WC.

Future Sci OA. 2015 Nov 1;1(3):FSO7. doi: 10.4155/fso.15.1. eCollection 2015 Nov. No abstract available.

11.

The interplay between cell signalling and the mevalonate pathway in cancer.

Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ.

Nat Rev Cancer. 2016 Nov;16(11):718-731. doi: 10.1038/nrc.2016.76. Epub 2016 Aug 26. Review.

PMID:
27562463
12.

MYC interaction with the tumor suppressive SWI/SNF complex member INI1 regulates transcription and cellular transformation.

Stojanova A, Tu WB, Ponzielli R, Kotlyar M, Chan PK, Boutros PC, Khosravi F, Jurisica I, Raught B, Penn LZ.

Cell Cycle. 2016 Jul 2;15(13):1693-705. doi: 10.1080/15384101.2016.1146836. Epub 2016 Jun 7.

13.

ChromNet: Learning the human chromatin network from all ENCODE ChIP-seq data.

Lundberg SM, Tu WB, Raught B, Penn LZ, Hoffman MM, Lee SI.

Genome Biol. 2016 Apr 30;17:82. doi: 10.1186/s13059-016-0925-0.

14.

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.

Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, Gebbia M, Lang KS, Giaever G, Nislow C, Moffat J, Penn LZ.

Oncotarget. 2015 Sep 29;6(29):26909-21. doi: 10.18632/oncotarget.4817.

15.

BioID data of c-MYC interacting protein partners in cultured cells and xenograft tumors.

Chan PK, Srikumar T, Dingar D, Kalkat M, Penn LZ, Raught B.

Data Brief. 2014 Oct 14;1:76-8. doi: 10.1016/j.dib.2014.10.001. eCollection 2014 Dec.

16.

AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress.

Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W, Skrtic M, Jhas B, Hurren R, Gronda M, Wang X, Jitkova Y, Sukhai MA, Lin FH, Maclean N, Laister R, Goard CA, Mullen PJ, Xie S, Penn LZ, Rogers IM, Dick JE, Minden MD, Schimmer AD.

Blood. 2015 Mar 26;125(13):2120-30. doi: 10.1182/blood-2014-08-594408. Epub 2015 Jan 28.

17.

Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.

Starmans MH, Pintilie M, Chan-Seng-Yue M, Moon NC, Haider S, Nguyen F, Lau SK, Liu N, Kasprzyk A, Wouters BG, Der SD, Shepherd FA, Jurisica I, Penn LZ, Tsao MS, Lambin P, Boutros PC.

Clin Cancer Res. 2015 Mar 15;21(6):1477-86. doi: 10.1158/1078-0432.CCR-14-1749. Epub 2015 Jan 21.

18.

Identification of c-MYC SUMOylation by mass spectrometry.

Kalkat M, Chan PK, Wasylishen AR, Srikumar T, Kim SS, Ponzielli R, Bazett-Jones DP, Raught B, Penn LZ.

PLoS One. 2014 Dec 18;9(12):e115337. doi: 10.1371/journal.pone.0115337. eCollection 2014.

19.

BioID identifies novel c-MYC interacting partners in cultured cells and xenograft tumors.

Dingar D, Kalkat M, Chan PK, Srikumar T, Bailey SD, Tu WB, Coyaud E, Ponzielli R, Kolyar M, Jurisica I, Huang A, Lupien M, Penn LZ, Raught B.

J Proteomics. 2015 Apr 6;118:95-111. doi: 10.1016/j.jprot.2014.09.029. Epub 2014 Oct 18.

PMID:
25452129
20.

Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one.

Pandyra A, Penn LZ.

Mol Cell Oncol. 2014 Dec 31;1(4):e969133. doi: 10.4161/23723548.2014.969133. eCollection 2014 Oct-Dec.

21.

Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop.

Pandyra A, Mullen PJ, Kalkat M, Yu R, Pong JT, Li Z, Trudel S, Lang KS, Minden MD, Schimmer AD, Penn LZ.

Cancer Res. 2014 Sep 1;74(17):4772-82. doi: 10.1158/0008-5472.CAN-14-0130. Epub 2014 Jul 3.

22.

The role of ligand density and size in mediating quantum dot nuclear transport.

Tang PS, Sathiamoorthy S, Lustig LC, Ponzielli R, Inamoto I, Penn LZ, Shin JA, Chan WC.

Small. 2014 Oct 29;10(20):4182-92. doi: 10.1002/smll.201401056. Epub 2014 Jul 2.

PMID:
24990622
23.

Myc and its interactors take shape.

Tu WB, Helander S, Pilstål R, Hickman KA, Lourenco C, Jurisica I, Raught B, Wallner B, Sunnerhagen M, Penn LZ.

Biochim Biophys Acta. 2015 May;1849(5):469-83. doi: 10.1016/j.bbagrm.2014.06.002. Epub 2014 Jun 14. Review.

PMID:
24933113
24.

Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.

Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ.

Breast Cancer Res Treat. 2014 Jan;143(2):301-12. doi: 10.1007/s10549-013-2800-y. Epub 2013 Dec 17.

PMID:
24337703
25.

MYC phosphorylation at novel regulatory regions suppresses transforming activity.

Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, Chan PK, Mullen PJ, Huang L, Meyer N, Raught B, Boutros PC, Penn LZ.

Cancer Res. 2013 Nov 1;73(21):6504-15. doi: 10.1158/0008-5472.CAN-12-4063. Epub 2013 Sep 12.

26.

Identifying Myc interactors.

Ponzielli R, Tu WB, Jurisica I, Penn LZ.

Methods Mol Biol. 2013;1012:51-64. doi: 10.1007/978-1-62703-429-6_4.

PMID:
24006057
27.

Identifying gene locus associations with promyelocytic leukemia nuclear bodies using immuno-TRAP.

Ching RW, Ahmed K, Boutros PC, Penn LZ, Bazett-Jones DP.

J Cell Biol. 2013 Apr 15;201(2):325-35. doi: 10.1083/jcb.201211097.

28.

MYC activity is negatively regulated by a C-terminal lysine cluster.

Wasylishen AR, Kalkat M, Kim SS, Pandyra A, Chan PK, Oliveri S, Sedivy E, Konforte D, Bros C, Raught B, Penn LZ.

Oncogene. 2014 Feb 20;33(8):1066-72. doi: 10.1038/onc.2013.36. Epub 2013 Feb 25.

PMID:
23435422
29.

Involvement of Toso in activation of monocytes, macrophages, and granulocytes.

Lang KS, Lang PA, Meryk A, Pandyra AA, Boucher LM, Pozdeev VI, Tusche MW, Göthert JR, Haight J, Wakeham A, You-Ten AJ, McIlwain DR, Merches K, Khairnar V, Recher M, Nolan GP, Hitoshi Y, Funkner P, Navarini AA, Verschoor A, Shaabani N, Honke N, Penn LZ, Ohashi PS, Häussinger D, Lee KH, Mak TW.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2593-8. doi: 10.1073/pnas.1222264110. Epub 2013 Jan 28.

30.

Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding.

Andresen C, Helander S, Lemak A, Farès C, Csizmok V, Carlsson J, Penn LZ, Forman-Kay JD, Arrowsmith CH, Lundström P, Sunnerhagen M.

Nucleic Acids Res. 2012 Jul;40(13):6353-66. Epub 2012 Mar 28.

31.

Targeting tumor cell metabolism with statins.

Clendening JW, Penn LZ.

Oncogene. 2012 Nov 29;31(48):4967-78. doi: 10.1038/onc.2012.6. Epub 2012 Feb 6. Review.

PMID:
22310279
32.

Myc: the beauty and the beast.

Wasylishen AR, Penn LZ.

Genes Cancer. 2010 Jun;1(6):532-41. doi: 10.1177/1947601910378024.

33.

New model systems provide insights into Myc-induced transformation.

Wasylishen AR, Stojanova A, Oliveri S, Rust AC, Schimmer AD, Penn LZ.

Oncogene. 2011 Aug 25;30(34):3727-34. doi: 10.1038/onc.2011.88. Epub 2011 Mar 28.

34.

Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.

Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ.

Int J Cancer. 2010 Dec 15;127(12):2936-48. doi: 10.1002/ijc.25295.

35.

Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair.

Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG.

Cancer Res. 2010 Nov 1;70(21):8748-59. doi: 10.1158/0008-5472.CAN-10-0944. Epub 2010 Oct 12.

36.

Dysregulation of the mevalonate pathway promotes transformation.

Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15051-6. doi: 10.1073/pnas.0910258107. Epub 2010 Aug 9.

37.

Characterization of the apoptotic response of human leukemia cells to organosulfur compounds.

Wong WW, Boutros PC, Wasylishen AR, Guckert KD, O'Brien EM, Griffiths R, Martirosyan AR, Bros C, Jurisica I, Langler RF, Penn LZ.

BMC Cancer. 2010 Jul 2;10:351. doi: 10.1186/1471-2407-10-351.

38.

Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma.

Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, Jurisica I, Trudel S, Penn LZ.

Blood. 2010 Jun 10;115(23):4787-97. doi: 10.1182/blood-2009-07-230508. Epub 2010 Apr 1.

PMID:
20360469
39.

Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.

Martirosyan A, Clendening JW, Goard CA, Penn LZ.

BMC Cancer. 2010 Mar 18;10:103. doi: 10.1186/1471-2407-10-103.

40.

Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues.

Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCready D, Wong D, Gerster K, Waldron L, Jurisica I, Penn LZ, Liu FF.

Lab Invest. 2009 May;89(5):597-606. doi: 10.1038/labinvest.2009.12. Epub 2009 Mar 16. Erratum in: Lab Invest. 2009 Jun;89(6):726. Waldron, Levi [added].

41.

The role of INI1/hSNF5 in gene regulation and cancer.

Stojanova A, Penn LZ.

Biochem Cell Biol. 2009 Feb;87(1):163-77. doi: 10.1139/O08-113. Review.

PMID:
19234532
42.

Absence of caspase-3 protects pancreatic {beta}-cells from c-Myc-induced apoptosis without leading to tumor formation.

Radziszewska A, Schroer SA, Choi D, Tajmir P, Radulovich N, Ho JC, Wang L, Liadis N, Hakem R, Tsao MS, Penn LZ, Evan GI, Woo M.

J Biol Chem. 2009 Apr 17;284(16):10947-56. doi: 10.1074/jbc.M806960200. Epub 2009 Feb 12.

43.

Prognostic gene signatures for non-small-cell lung cancer.

Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, Tsao MS, Penn LZ, Jurisica I.

Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2824-8. doi: 10.1073/pnas.0809444106. Epub 2009 Feb 5.

44.

Reflecting on 25 years with MYC.

Meyer N, Penn LZ.

Nat Rev Cancer. 2008 Dec;8(12):976-90. doi: 10.1038/nrc2231. Review.

PMID:
19029958
45.

Optimization of experimental design parameters for high-throughput chromatin immunoprecipitation studies.

Ponzielli R, Boutros PC, Katz S, Stojanova A, Hanley AP, Khosravi F, Bros C, Jurisica I, Penn LZ.

Nucleic Acids Res. 2008 Dec;36(21):e144. doi: 10.1093/nar/gkn735. Epub 2008 Oct 21.

46.

Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function.

Beheshti Zavareh R, Lau KS, Hurren R, Datti A, Ashline DJ, Gronda M, Cheung P, Simpson CD, Liu W, Wasylishen AR, Boutros PC, Shi H, Vengopal A, Jurisica I, Penn LZ, Reinhold VN, Ezzat S, Wrana J, Rose DR, Schachter H, Dennis JW, Schimmer AD.

Cancer Res. 2008 Aug 15;68(16):6688-97. doi: 10.1158/0008-5472.CAN-07-6833. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692.

47.

Three-gene prognostic classifier for early-stage non small-cell lung cancer.

Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, Johnston MR, Darling G, Keshavjee S, Waddell TK, Liu N, Lau D, Penn LZ, Shepherd FA, Jurisica I, Der SD, Tsao MS.

J Clin Oncol. 2007 Dec 10;25(35):5562-9.

PMID:
18065728
48.

CUL7 is a novel antiapoptotic oncogene.

Kim SS, Shago M, Kaustov L, Boutros PC, Clendening JW, Sheng Y, Trentin GA, Barsyte-Lovejoy D, Mao DY, Kay R, Jurisica I, Arrowsmith CH, Penn LZ.

Cancer Res. 2007 Oct 15;67(20):9616-22.

49.

Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.

Zhu CQ, Popova SN, Brown ER, Barsyte-Lovejoy D, Navab R, Shih W, Li M, Lu M, Jurisica I, Penn LZ, Gullberg D, Tsao MS.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11754-9. Epub 2007 Jun 28.

50.

Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma.

Wong WW, Clendening JW, Martirosyan A, Boutros PC, Bros C, Khosravi F, Jurisica I, Stewart AK, Bergsagel PL, Penn LZ.

Mol Cancer Ther. 2007 Jun;6(6):1886-97.

Supplemental Content

Support Center